NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Launches New Molecular Lung Cancer Test
Interpace Diagnostics Group (NASDAQ: IDXG) shares are up 6% after the company this morning announced the launch of its new lung cancer test, MVPdX™. The test distinguishes the local recurrence of cancer versus new primary cancer formation. The company’s Medicare Administrative Carrier and many commercial carriers already cover the MVPdX test. “This represents a significant milestone for the company as we expand our menu to include an entirely new vertical line of business in lung assays using our already proven technology. We believe this initiative will further diversify our product offering while potentially providing for further expansion of our revenues,”…







